SCHEMBL6086677

SCHEMBL6086677

Cc1ccc2oc(-c3c[nH]nc3-c3ccc(NC(=O)Cc4ccc(I)cc4)cc3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
P2RY14 Q15391 4/20 0.56
KDR P35968 5/20 0.56
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
HPGD P15428 3/20 0.54
HSD17B10 Q99714 3/20 0.54
RXFP1 Q9HBX9 3/20 0.54
MEN1 O00255 1/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
PPARG P37231 1/20 0.54
KMT2A Q03164 1/20 0.54
NCOA2 Q15596 1/20 0.54
NCOA1 Q15788 1/20 0.54
TP53 P04637 4/20 0.53
CETP P11597 1/20 0.53
CEPT1 Q9Y6K0 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084754 0.92 MAPT (0.67) MAPTP2RY14KDRKDM4EALDH1A1
SCHEMBL6084737 0.92 TP53 (0.64) MAPTP2RY14KDRKDM4EALDH1A1
SCHEMBL6084624 0.89 MAPT (0.60) MAPTP2RY14KDRKDM4EALDH1A1
SCHEMBL6086537 0.88 CETP (0.55) MAPTKDRALDH1A1HPGDHSD17B10
SCHEMBL6085184 0.87 MAPT (0.58) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6086216 0.87 P2RY14 (0.63) MAPTP2RY14KDRHSD17B10RXFP1
SCHEMBL6085674 0.85 KDR (0.53) MAPTP2RY14KDRKDM4EALDH1A1
SCHEMBL6085428 0.84 P2RY14 (0.69) MAPTP2RY14KDRKDM4EALDH1A1
SCHEMBL6085509 0.83 SMN1; SMN2 (0.63) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6085551 0.82 SMN1; SMN2 (0.58) MAPTKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885P2RY14 1920/4885KDR 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.